Skip to main content

Main menu

  • Home
  • Content
    • Current
      • JNMT Supplement
    • Ahead of print
    • Past Issues
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Permissions
    • Continuing Education
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine Technology
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine Technology

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Permissions
    • Continuing Education
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow SNMMI on Twitter
  • Visit SNMMI on Facebook
  • Join SNMMI on LinkedIn
  • Subscribe to JNMT RSS feeds
OtherQuality & Practice Management (JNMT)

Stability matters: Radiochemical stability of therapeutic radiopharmaceutical of 177Lu-PSMA-I&T

Madhusudan Vyas, Remy Lim, Jessica Fegan and Rudresh Chandrashekar
Journal of Nuclear Medicine Technology June 2022, jnmt.121.262423; DOI: https://doi.org/10.2967/jnmt.121.262423
Madhusudan Vyas
Department of Nuclear Medicine and PET-CT, Mercy Radiology, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Remy Lim
Department of Nuclear Medicine and PET-CT, Mercy Radiology, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jessica Fegan
Department of Nuclear Medicine and PET-CT, Mercy Radiology, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rudresh Chandrashekar
Department of Nuclear Medicine and PET-CT, Mercy Radiology, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Abstract

Labelling radiopharmaceuticals and testing the quality of the labelled product before injecting it into patients are standard operating procedures in the Nuclear Medicine department. There is a different shelf life for each labelled product, which determines how long a product can maintain in-vitro stability before it needs to be discarded. Lutetium-177 (177Lu) is a radioactive isotope that is increasingly being accepted into the treatment paradigm for palliation of advanced-stage tumours, including metastatic castration-resistant prostate cancer (mCRPC) and neuroendocrine tumours (NET). In our institution, synthesis of 177Lu with prostate-specific membrane antigen imaging and therapy (PSMA-I & T) for palliation of mCRPC is performed on Eckert & Ziegler Eurotope’s Modular-Lab Pharm Tracer® automated synthesis system. Sterile GMP-certified no-carrier-added 177Lu is supplied by Australia’s Nuclear Science and Technology Organization (ANSTO). Following each synthesis, the final product quality is evaluated by High-performance liquid chromatography (HPLC) and instant thin-layer chromatography (ITLC) at three different time points: 0 hours, 24 hours, and 48 hours. Between February 2020 to October 2020, the quality of 35 batches of 177Lu-PSMA-I & T was evaluated. The average radiochemical purity of ITLC-SG was found to be greater than 99 percent (99.70±05%), and HPLC was greater than 98 percent (98.60±0.05%). Our findings demonstrate that automated synthesis of 177Lu-PSMA-I & T with Eckert & Ziegler Eurotope’s Modular-Lab Pharm Tracer® can remain stable for 48 hours post labelling.

  • Quality Assurance
  • Radiochemistry
  • Radionuclide Therapy
  • High-performance liquid chromatography (HPLC)
  • Instant thin-layer chromatography (ITLC)
  • Lutetium-177 (Lu177)
  • Prostate-specific membrane antigen Image and therapy (PSMA )

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

SNMMI members

SNMMI Member Login

Login to the site using your SNMMI member credentials

Individuals

Non-Member Login

Login as an individual user

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine Technology: 50 (4)
Journal of Nuclear Medicine Technology
Vol. 50, Issue 4
December 1, 2022
  • Table of Contents
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine Technology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Stability matters: Radiochemical stability of therapeutic radiopharmaceutical of 177Lu-PSMA-I&T
(Your Name) has sent you a message from Journal of Nuclear Medicine Technology
(Your Name) thought you would like to see the Journal of Nuclear Medicine Technology web site.
Citation Tools
Stability matters: Radiochemical stability of therapeutic radiopharmaceutical of 177Lu-PSMA-I&T
Madhusudan Vyas, Remy Lim, Jessica Fegan, Rudresh Chandrashekar
Journal of Nuclear Medicine Technology Jun 2022, jnmt.121.262423; DOI: 10.2967/jnmt.121.262423

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Stability matters: Radiochemical stability of therapeutic radiopharmaceutical of 177Lu-PSMA-I&T
Madhusudan Vyas, Remy Lim, Jessica Fegan, Rudresh Chandrashekar
Journal of Nuclear Medicine Technology Jun 2022, jnmt.121.262423; DOI: 10.2967/jnmt.121.262423
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Quality & Practice Management (JNMT)

  • Post-treatment Exposure Rates for 90Y Microsphere Patients: A Comparison of Products
Show more Quality & Practice Management (JNMT)

Basic (Quality Assurance)

  • Post-treatment Exposure Rates for 90Y Microsphere Patients: A Comparison of Products
Show more Basic (Quality Assurance)

Similar Articles

Keywords

  • Quality Assurance
  • Radiochemistry
  • Radionuclide Therapy
  • High-performance liquid chromatography (HPLC)
  • Instant thin-layer chromatography (ITLC)
  • Lutetium-177 (Lu177)
  • Prostate-specific membrane antigen Image and therapy (PSMA )
SNMMI

© 2023 Journal of Nuclear Medicine Technology

Powered by HighWire